» Articles » PMID: 29480838

Predicting Poor Adherence to Antiretroviral Therapy Among Treatment-naïve Veterans Infected with Human Immunodeficiency Virus

Overview
Specialty General Medicine
Date 2018 Feb 27
PMID 29480838
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies suggested that human immunodeficiency virus (HIV) infected patients at risk of poor adherence were not distinguishable only based on the baseline characteristics. This study is to identify patient characteristics that would be consistently associated with poor adherence across regimens and to understand the associations between initial and long-term adherence. HIV treatment-naïve patients initiated on protease inhibitors, nonnucleoside reverse transcriptase inhibitors, or integrase strand transfer inhibitors were identified from the Veteran Health Administration system. Initial adherence measured as initial coverage ratio (ICR) and long-term adherence measured as thereafter 1-year proportion days covered (PDC) of base agent and complete regimen were estimated for each patient. The patients most likely to exhibit poor adherence were African-American, with lower socioeconomic status, and healthier. The initial coverage ratio of base agent and complete regimen were highly correlated, but the correlations between ICR and thereafter 1-year PDC were low. However, including initial adherence as a predictor in predictive model would substantially increase predictive accuracy of future adherence.

Citing Articles

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy.

Andreatta K, Sax P, Wohl D, DAntoni M, Liu H, Hindman J J Antimicrob Chemother. 2024; 80(1):281-291.

PMID: 39556192 PMC: 11695908. DOI: 10.1093/jac/dkae407.


A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions.

Kakubu M, Frans K, Gibutai N, Katoto P SAGE Open Med Case Rep. 2022; 10:2050313X221144209.

PMID: 36569036 PMC: 9772926. DOI: 10.1177/2050313X221144209.


Factors associated with anti-retroviral therapy adherence among patients living with HIV during the COVID-19 pandemic: A cross-sectional study.

Suryana K, Suharsono H, Indrayani A, Wisma Ariani L, Putra W, Yaniswari N Front Psychiatry. 2022; 13:824062.

PMID: 36186875 PMC: 9515442. DOI: 10.3389/fpsyt.2022.824062.


Multi-tablet, Single-Tablet, or Long-Acting Antiretroviral Treatment for HIV: A Cross-sectional Study of Patient Preferences in the United States and Spain.

Carracedo A, Oliveira V, Saz J, Pujol F, Milinkovic A, Webel A J Assoc Nurses AIDS Care. 2022; 33(6):638-645.

PMID: 35878049 PMC: 11494151. DOI: 10.1097/JNC.0000000000000343.


Predicting the individualized risk of poor adherence to ART medication among adolescents living with HIV in Uganda: the Suubi+Adherence study.

Brathwaite R, Ssewamala F, Neilands T, Okumu M, Mutumba M, Damulira C J Int AIDS Soc. 2021; 24(6):e25756.

PMID: 34105865 PMC: 8188571. DOI: 10.1002/jia2.25756.


References
1.
Blumenthal D, Singal G, Mangla S, Macklin E, Chung D . Predicting Non-Adherence with Outpatient Colonoscopy Using a Novel Electronic Tool that Measures Prior Non-Adherence. J Gen Intern Med. 2015; 30(6):724-31. PMC: 4441666. DOI: 10.1007/s11606-014-3165-6. View

2.
DiMatteo M, Haskard K, Williams S . Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007; 45(6):521-8. DOI: 10.1097/MLR.0b013e318032937e. View

3.
Pandhi D, Ailawadi P . Initiation of antiretroviral therapy. Indian J Sex Transm Dis AIDS. 2014; 35(1):1-11. PMC: 4066590. DOI: 10.4103/0253-7184.132399. View

4.
Hong S, Jerger L, Jonas A, Badi A, Cohen S, Nachega J . Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. PLoS One. 2013; 8(2):e56307. PMC: 3585291. DOI: 10.1371/journal.pone.0056307. View

5.
Samji H, Cescon A, Hogg R, Modur S, Althoff K, Buchacz K . Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12):e81355. PMC: 3867319. DOI: 10.1371/journal.pone.0081355. View